$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000153217618000020 Filed on May 03, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$1.511B	$1.319B
YoY Change	14.59%	9.84%
Cost Of Revenue	$69.24M	$61.25M
YoY Change	13.04%	-22.41%
Gross Profit	$1.442B	$1.258B
YoY Change	14.67%	12.11%
Gross Profit Margin	95.42%	95.36%
Selling, General & Admin	$330.8M	$296.8M
YoY Change	11.44%	2.47%
% of Gross Profit	22.94%	23.6%
Research & Development	$498.6M	$507.4M
YoY Change	-1.74%	7.94%
% of Gross Profit	34.57%	40.35%
Depreciation & Amortization	$36.40M	$38.12M
YoY Change	-4.5%	65.88%
% of Gross Profit	2.52%	3.03%
Operating Expenses	$829.4M	$804.3M
YoY Change	3.12%	5.86%
Operating Profit	$567.2M	$430.5M
YoY Change	31.74%	30.74%
Interest Expense	$6.400M	$7.501M
YoY Change	-14.68%	-384.13%
% of Operating Profit	1.13%	1.74%
Other Income/Expense, Net	$18.20M	$1.747M
YoY Change	941.79%	107.24%
Pretax Income	$585.4M	$432.3M
YoY Change	35.42%	30.94%
Income Tax	$107.4M	$183.4M
% Of Pretax Income	18.35%	42.42%
Net Earnings	$478.0M	$248.9M
YoY Change	92.04%	37.22%
Net Earnings / Revenue	31.62%	18.87%
Basic Earnings Per Share	$4.44	$2.36
Diluted Earnings Per Share	$4.16	$2.16
COMMON SHARES
Basic Shares Outstanding	107.6M shares	105.6M shares
Diluted Shares Outstanding	114.9M shares	115.1M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.625B	$1.307B
YoY Change	24.33%	53.95%
Cash & Equivalents	$1.020B	$811.8M
Short-Term Investments	$605.0M	$495.0M
Other Short-Term Assets	$377.0M	$291.0M
YoY Change	29.55%	79.63%
Inventory	$820.4M	$466.6M
Prepaid Expenses
Receivables	$1.532B	$1.340B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$4.545B	$3.669B
YoY Change	23.86%	17.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.395B	$2.277B
YoY Change	5.17%	36.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.822B	$968.0M
YoY Change	88.22%	74.41%
Other Assets	$78.98M	$37.09M
YoY Change	112.97%	540.42%
Total Long-Term Assets	$4.828B	$4.148B
YoY Change	16.39%	49.69%
TOTAL ASSETS
Total Short-Term Assets	$4.545B	$3.669B
Total Long-Term Assets	$4.828B	$4.148B
Total Assets	$9.373B	$7.817B
YoY Change	19.9%	32.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$208.0M	$142.0M
YoY Change	46.48%	17.36%
Accrued Expenses	$666.0M	$469.0M
YoY Change	42.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$7.000M
YoY Change
Total Short-Term Liabilities	$1.266B	$1.308B
YoY Change	-3.25%	42.25%
LONG-TERM LIABILITIES
Long-Term Debt	$705.0M	$700.0M
YoY Change	0.71%	93.37%
Other Long-Term Liabilities	$169.9M	$106.2M
YoY Change	59.93%	-12.19%
Total Long-Term Liabilities	$169.9M	$106.2M
YoY Change	59.93%	-12.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.266B	$1.308B
Total Long-Term Liabilities	$169.9M	$106.2M
Total Liabilities	$2.805B	$2.951B
YoY Change	-4.96%	37.95%
SHAREHOLDERS EQUITY
Retained Earnings	$3.288B	$1.997B
YoY Change	64.62%	96.1%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$316.2M	$316.2M
YoY Change	0.0%	2.85%
Treasury Stock Shares	3.764M shares	3.764M shares
Shareholders Equity	$6.568B	$4.866B
YoY Change
Total Liabilities & Shareholders Equity	$9.373B	$7.817B
YoY Change	19.9%	32.4%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$478.0M	$248.9M
YoY Change	92.04%	37.22%
Depreciation, Depletion And Amortization	$36.40M	$38.12M
YoY Change	-4.5%	65.88%
Cash From Operating Activities	$618.8M	$355.9M
YoY Change	73.87%	691.08%
INVESTING ACTIVITIES
Capital Expenditures	-$79.40M	-$50.50M
YoY Change	57.23%	-51.49%
Acquisitions
YoY Change
Other Investing Activities	-$346.0M	-$89.70M
YoY Change	285.73%	-248.51%
Cash From Investing Activities	-$425.4M	-$140.1M
YoY Change	203.55%	220.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$13.40M	$16.67M
YoY Change	-180.37%	-57.58%
Debt Paid & Issued, Net		$12.86M
YoY Change		2050.67%
Cash From Financing Activities	$13.40M	$60.81M
YoY Change	-77.96%	-129.49%
NET CHANGE
Cash From Operating Activities	$618.8M	$355.9M
Cash From Investing Activities	-$425.4M	-$140.1M
Cash From Financing Activities	$13.40M	$60.81M
Net Change In Cash	$206.8M	$276.6M
YoY Change	-25.23%	-234.99%
FREE CASH FLOW
Cash From Operating Activities	$618.8M	$355.9M
Capital Expenditures	-$79.40M	-$50.50M
Free Cash Flow	$698.2M	$406.4M
YoY Change	71.8%	172.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2016Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	28200000	USD
CY2017Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	32300000	USD
CY2017Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	41800000	USD
CY2017Q1	regn	Costofmanufacturing Costofmanufacturing	22915000	USD
CY2018Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	40200000	USD
CY2017Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	703453000	USD
CY2018Q1	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	704645000	USD
CY2018Q1	regn	Costofmanufacturing Costofmanufacturing	45655000	USD
CY2017Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	177746000	USD
CY2018Q1	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	231447000	USD
CY2017Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	379936000	USD
CY2018Q1	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	406778000	USD
CY2017Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	484000	shares
CY2018Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	14000	shares
CY2018Q1	regn	Loss Contingency Damages Soughtperunitproduced. LossContingencyDamagesSoughtperunitproduced.	10000	EUR
CY2017Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	193939000	USD
CY2018Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	247928000	USD
CY2017Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	242014000	USD
CY2018Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	243141000	USD
CY2017Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	178183000	USD
CY2018Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	207611000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1538642000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1531936000	USD
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	193684000	USD
CY2018Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	168855000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	637162000	USD
CY2018Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	666216000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	640000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15594000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3512833000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3611599000	USD
CY2017Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	106970000	USD
CY2018Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	140763000	USD
CY2017Q4	us-gaap	Assets Assets	8764286000	USD
CY2018Q1	us-gaap	Assets Assets	9372696000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4335030000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	4544732000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2020556000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2358371000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2210000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1978000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8926000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19781000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2027272000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2376174000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3583000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5197000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	8926000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	19781000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	1370760000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	1728280000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5343000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	14584000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	1044084000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	1417229000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	326676000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	311051000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1426773000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1752910000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	593783000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	605461000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2020556000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2358371000	USD
CY2017Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	0	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	201200000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	811773000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812733000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1019491000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	276570000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	206758000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	547703000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	824273000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	825233000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1031991000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	255887000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	468339000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	61253000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	69243000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	888449000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	944254000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142392000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	160466000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	249263000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	257967000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	506291000	USD
CY2018Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	532268000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38115000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36358000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.36
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.44
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.16
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.424
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.183
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2018Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2018Q1	us-gaap	Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness GainLossOnInterestRateCashFlowHedgeIneffectiveness	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	432289000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	585398000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	183358000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107418000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	187695000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76654000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	137928000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30408000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	40988000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	6366000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12400000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-54596000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	69744000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	88760000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20325000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-68836000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9050000	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7244000	shares
CY2017Q1	us-gaap	Interest Expense InterestExpense	7501000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	6439000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21791000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	22848000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	726138000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	820397000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	190045000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	201429000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	302042000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	374505000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2620208000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	2805052000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8764286000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9372696000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1135483000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1265740000	USD
CY2018Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	EUR
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	596847000	USD
CY2018Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	605461000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1486494000	USD
CY2018Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1821985000	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2018Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60812000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13427000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140143000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-425412000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	355901000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	618743000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	248931000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	477980000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1747000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18167000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	430542000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	567231000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77866000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78984000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	1439000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6956000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-11080000	USD
CY2017Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	212260000	USD
CY2018Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	221615000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152073000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	169922000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3956000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4193000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9248000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24606000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	56440000	USD
CY2018Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	86158000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	208694000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	601313000	USD
CY2017Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	50461000	USD
CY2018Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	79375000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	224972000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	155451000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16673000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13427000	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	57000000	USD
CY2018Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	119012000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	255276000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2358605000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2394727000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	12861000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	507435000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	498586000	USD
CY2017Q1	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2018Q1	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2946733000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3287767000	USD
CY2017Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	210367000	USD
CY2018Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	189490000	USD
CY2017Q1	us-gaap	Revenues Revenues	1318991000	USD
CY2018Q1	us-gaap	Revenues Revenues	1511485000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	858245000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	987909000	USD
CY2018Q1	us-gaap	Securities Owned Not Readily Marketable SecuritiesOwnedNotReadilyMarketable	37500000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	296846000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	330770000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	133789000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	82422000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6144078000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	6567644000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2017Q1	us-gaap	Unrealized Gain On Securities UnrealizedGainOnSecurities	5400000	USD
CY2018Q1	us-gaap	Unrealized Gain On Securities UnrealizedGainOnSecurities	9400000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45851000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	56033000	USD
CY2017Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	85302000	USD
CY2018Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	109319000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	89603000	USD
CY2018Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	111381000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	79421000	USD
CY2018Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	87364000	USD
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9534000	shares
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	7258000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115106000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114906000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105572000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107648000	shares
CY2018Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires a lessee to recognize on its balance sheet (for both finance and operating leases) a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. We plan to adopt this standard in the first quarter of 2019 and are evaluating the impact that this guidance will have on our financial statements, including related disclosures. The new standard will result in the Company recording additional assets and corresponding liabilities related to operating leases; however, we do not expect the standard to have a material impact to our Consolidated Balance Sheets. The ultimate impact that the new standard will have will depend on the total amount of the Company's lease commitments as of the adoption date. We are in process of implementing a new lease accounting software system, and expect the implementation of the new standard to have a significant impact on our internal controls and processes.</font></div></div>

Files In Submission

Name	View Source	Status
0001532176-18-000020-index-headers.html	Edgar Link	pending
0001532176-18-000020-index.html	Edgar Link	pending
0001532176-18-000020.txt	Edgar Link	pending
0001532176-18-000020-xbrl.zip	Edgar Link	pending
exhibit102regeneronsa_image1.gif	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-033118x10q.htm	Edgar Link	pending
regn-20180331.xml	Edgar Link	completed
regn-20180331.xsd	Edgar Link	pending
regn-20180331_cal.xml	Edgar Link	unprocessable
regn-20180331_def.xml	Edgar Link	unprocessable
regn-20180331_lab.xml	Edgar Link	unprocessable
regn-20180331_pre.xml	Edgar Link	unprocessable
regn-ex_101xretirementagre.htm	Edgar Link	pending
regn-ex_102xletteragreemen.htm	Edgar Link	pending
regn-ex_311x03312018x10q.htm	Edgar Link	pending
regn-ex_312x03312018x10q.htm	Edgar Link	pending
regn-ex_32x03312018x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2018 Q1 Form 10-Q Financial Statement

#000153217618000020 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2018 Q1 Form 10-Q Financial Statement

#000153217618000020 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn